NCT00157326已完成2 期
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Tadalafil (5mg and 20mg) Administered Once Daily to Subjects With Mild to Moderate Hypertension
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 180
- 试验地点
- 1
- 主要终点
- The primary efficacy measurement of this study is the mean change after 8 weeks of treatment from baseline in cuff seated trough diastolic blood pressure, cuff seated systolic blood pressures and automated blood pressure monitoring
研究概览
简要总结
Purpose: The primary objective of this study is to evaluate the efficacy and safety of tadalafil when administered once daily at doses of 5 and 20 mg to adult subjects for 8 weeks with mild to moderate hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Have a documented medical history of hypertension.
- •Have cuff seated diastolic blood pressure values greater than or equal to 95 and less than or equal to 104 mm at study entry
- •Have a negative serum pregnancy test at the time of enrollment and agree to use two medically reliable methods of contraception until study completion, if female is of child-bearing potential, between menarche and 1 year post menopause and not surgically sterilized.
- •Are able to comply with study procedures and visits
排除标准
- •Have resistant hypertension or systolic hypertension.
- •Are obese, defined as having body mass index (BMI) greater than or equal to
- •Are females who are pregnant or breast feeding.
- •Have a history of severe renal insufficiency or significant thyroid, renal or hepatic disease.
- •Have a glycosylated hemoglobin A1c (HbA1c) greater than or equal to 10% during the screening period.
- •Have significant anemia.
- •Have a significant or unstable cardiac history such as history of heart attack, unstable angina, or stroke within 6 months of study entry, history of angina that was treated with long- or short-acting nitrates within 90 days of study entry, history of coronary artery bypass graft surgery or cardiac angioplasty within 90 days of study entry, history of abnormal heart rhythms such as sick sinus syndrome or 2nd- or 3rd-degree AV block, chronic atrial fibrillation or recurrent atrial tachyarrhythmia, a history of recurrent ventricular tachycardia, or symptomatic bradycardia, a history of sudden cardiac arrest.
- •Have symptomatic heart failure requiring treatment, or significant disease of the heart valves.
- •Have been treated for severe asthma, bronchospasm, or COPD within 3 months of study entry.
- •Have severe peripheral vascular disease.
- •Have a documented diagnosis of sleep apnea.
结局指标
主要结局
The primary efficacy measurement of this study is the mean change after 8 weeks of treatment from baseline in cuff seated trough diastolic blood pressure, cuff seated systolic blood pressures and automated blood pressure monitoring
次要结局
- Safety will be assessed by evaluating all reported adverse events and changes in clinical laboratory values, ECGs, and vital signs
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Effect of Tadalafil Once a Day in Men With Erectile DysfunctionErectile DysfunctionNCT00836693Eli Lilly and Company217
已完成
3 期
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary SymptomsEnlarged ProstateBenign Prostatic HyperplasiaNCT01139762Eli Lilly and Company696
已完成
2 期
Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach EmptyingGastroparesisNCT00050609Eli Lilly and Company2
已完成
3 期
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord InjurySpinal Cord InjuriesErectile DysfunctionNCT00421083Eli Lilly and Company180
已完成
3 期
PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial HypertensionPulmonary HypertensionNCT00125918Eli Lilly and Company406